Dr. Yeu examines risk factors for Demodex blepharitis, including patients with diabetes and immunosuppression.
This is a video synopsis/summary of a discussion involving Elizabeth Yeu, MD.
Dr. Yeu states that although socioeconomic status and hygiene are not risks for Demodex blepharitis, potential associations exist with older age, diabetes, immunosuppression, glaucoma drops, and contact lens wear. She notes that Demodex is a non–self-resolving process that increases over time, so likely manifests with greater severity in older patients. Critically, Demodex blepharitis has substantial psychosocial impact that is often overlooked. Data from the Atlas study showed that 80% of patients feel the disease negatively affects their daily life, with nearly half reporting self-consciousness about their eyes, difficulty driving at night, and problems wearing eye makeup. One-third of patients needed extra time for lid hygiene. Half of patients had symptoms for more than 4 years and one-third saw doctors for 2-plus years without a blepharitis diagnosis. This demonstrates the under-recognition of this condition. In summary, various medical conditions may increase risk for Demodex blepharitis, which increases with age. However the psychosocial burden is significant and warrants increased awareness to facilitate prompt diagnosis and treatment.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More